title: HIV and tuberculosis in India.
abstract: The global impact of the converging dual epidemics of tuberculosis (TB) and human immunodeficiency virus (HIV) is one of the major public health challenges of our time. The World Health Organization (WHO) reports 9.2 million new cases of TB in 2006 of whom 7.7% were HIV-infected. Tuberculosis is the most common opportunistic infection in HIV-infected patients as well as the leading cause of death. Further,there has been an increase in rates of drug resistant tuberculosis, including multi-drug (MDRTB) and extensively drug resistant TB (XDRTB), which are difficult to treat and contribute to increased mortality. The diagnosis of TB is based on sputum smear microscopy, a 100-year old technique and chest radiography,which has problems of specificity. Extra-pulmonary, disseminated and sputum smear negative manifestations are more common in patients with advanced immunosuppression. Newer diagnostic tests are urgently required that are not only sensitive and specific but easy to use in remote and resourc-poor settings. Treatment of HIV-TB co-infection is complex and associated with high pill burden, overlapping drug toxicities,risk of immune reconstitution inflammatory syndrome (IRIS) and challenges related to adherence. From a programmatic point of view, screening of all HIV-infected persons for tuberculosis and vice-versa will help identify co-infected patients who require treatment for both infections. This requires good coordination and communication between the TB and AIDS control programs, in India.
authors.affiliation: Deptartment of Clinical Research,Tuberculosis Research Centre, Mayor VR Ramanathan Road, Chetput, Chennai 600 031, India. doctorsoumya@yahoo.com
authors.forename: Soumya
authors.initials: S
authors.lastname: Swaminathan
authors.forename: G
authors.initials: G
authors.lastname: Nagendran
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use; D000904:Antibiotics, Antitubercular / Q000009:adverse effects / Q000627:therapeutic use; D004196:Disease Outbreaks / Q000517:prevention & control; D004347:Drug Interactions; D024901:Drug Resistance, Multiple, Bacterial; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D007194:India / Q000453:epidemiology; D008403:Mass Screening; D015995:Prevalence; D014376:Tuberculosis / Q000150:complications* / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy
chemical_list: D019380:Anti-HIV Agents; D000904:Antibiotics, Antitubercular